MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade

Chronological Source Flow
Back

AI Fusion Summary

MoonLake Immunotherapeutics shares jumped 5% after Rothschild Co Redburn upgraded to buy, raising target to $40 from $12. The stock opened at $17.20, trading volume 248k. HC Wainwright also lifted target to $40. Goldman Sachs downgraded from neutral.
20/03 07:32 defenseworld.net
3 Πηγές
20/03 07:54 defenseworld.net
20/03 10:14 defenseworld.net
Comments
Loading...
0